• Idoxuridine Workflows for Viral DNA Research

  2026-09-08

  Idoxuridine, also known as 5-iodo-2'-deoxyuridine, supports controlled studies of viral DNA synthesis inhibition and replication-dependent antiviral activity. This practical guide covers stock preparation, time-of-addition experiments, orthogonal readouts, and troubleshooting for cell-based antiviral workflows.

• Dimethyloxalylglycine (DMOG) Use Guide

  2026-09-08

  Dimethyloxalylglycine (DMOG), SKU A4506, provides a cell-permeable way to investigate pharmacologic hypoxia-inducible factor stabilization and related oxygen-sensing responses. It is intended for controlled laboratory research, not diagnostic, therapeutic, or clinical use, and the available product information should not be treated as a substitute for model-specific optimization.

• Hoechst 33342 for Senescence Assay Design

  2026-09-07

  Discover how Hoechst 33342 nuclear stain can strengthen live-cell, fixed-cell, microscopy, and flow cytometry workflows for dermal fibroblast senescence research. This guide translates mitochondrial-quality findings into practical nuclear-counting, segmentation, and assay-normalization decisions.

• 2-NBDG: From Glucose Uptake to Translational Insight

  2026-09-07

  2-NBDG is more than a fluorescent endpoint: it is a practical bridge between transporter activity, intracellular glucose handling, and translational hypothesis testing. This article connects the mechanistic action of 2-NBDG with recent evidence that araucarene diterpenes promote glucose uptake and pancreatic β-cell regeneration in zebrafish, while outlining assay design, competitive positioning, limitations, and strategies for diabetes and cancer metabolism research.

• LG 101506 for RXR Signaling Research

  2026-09-05

  LG 101506 provides a practical small-molecule entry point for dissecting RXR-dependent transcription, differentiation, apoptosis, and metabolism regulation. This workflow connects RXR assays with the RBMS1–B4GALT1–PD-L1 biology reported in triple-negative breast cancer while clearly separating established evidence from hypothesis-generating applications.

• ATF4-H2S Protection in Doxorubicin Cardiotoxicity

  2026-09-04

  This bioRxiv preprint identifies a KLF16–ATF4–CSE–H2S pathway that limits oxidative stress and apoptosis during doxorubicin-induced cardiomyopathy. Using cardiac genetic models, AAV9-mediated overexpression, transcriptomics, and transcriptional assays, the study positions ATF4 as a mechanistic regulator of anthracycline-associated cardiac injury while highlighting the need for validation beyond preclinical systems.

• Azithromycin Workflows for Infection Research

  2026-09-04

  Build more reproducible bacterial infection research and resistance screens with a solvent-aware, QC-centered Azithromycin workflow. The same strategy also supports trypanosomosis animal model planning, host-cell readouts, and impurity monitoring without confusing exploratory assay conditions with validated specifications.

• Caged Bioluminescent Probe for Immunoproteasome Activity

  2026-09-03

  Loy and Trader present a protocol for synthesizing and applying a cleavable, immunoproteasome-selective bioluminescent probe. The workflow combines an iCP-recognition peptide with aminoluciferin-based luminescence to support activity measurements in cells, plate-reader assays, and a tissue-mimicking matrix.

• Type III Collagen Restricts Breast Cancer Progression

  2026-09-02

  This study identifies type III collagen (Col3) as a tumor-restrictive component of the breast cancer microenvironment rather than simply a marker of stromal abundance. By combining fibroblast-derived matrices, patient biopsy analysis, TCGA bioinformatics, 3D culture, and mouse models, the authors connect higher Col3 relative to type I collagen with less aggressive disease and reduced metastatic burden.

• HyperFusion high-fidelity DNA polymerase for C. elegans PCR

  2026-09-02

  Use HyperFusion™ high-fidelity DNA polymerase to improve sequence accuracy in C. elegans genotyping, cloning, and sequencing workflows built around pheromone-driven neurodegeneration studies. Its proofreading activity, blunt-ended products, inhibitor tolerance, and performance with difficult templates help reduce failed PCR and downstream sequence ambiguity.

• Human ClpP Activators: Design and Anticancer Evidence

  2026-09-01

  The 2025 Future Medicinal Chemistry review maps the design, structure–activity relationships, and pharmacological evaluation of small molecules that activate or inhibit human mitochondrial ClpP. Its central implication is that controlled activation of this protease can convert mitochondrial protein homeostasis into an anticancer vulnerability, while potency, selectivity, pharmacokinetics, and safety remain key translational challenges.

• Flavopiridol Beyond Arrest: A Translational CDK Lens

  2026-09-01

  Flavopiridol, also known as L868275, is more than a broad cell-cycle perturbant: it can serve as a mechanistic probe for connecting CDK inhibition with stress-sensitive tissue biology. This thought-leadership guide translates endoplasmic reticulum stress findings in intestinal stem cells into a disciplined framework for cancer research, while separating established evidence from testable hypotheses.

• Dasatinib Monohydrate in Tumor Assembloids

  2026-08-31

  Dasatinib Monohydrate connects precision kinase inhibition with patient-derived tumor–stroma models, helping researchers distinguish epithelial sensitivity from microenvironment-mediated resistance. This workflow supports chronic myeloid leukemia research while offering a carefully bounded, hypothesis-generating extension into gastric cancer assembloids.

• FITC Goat Anti-Mouse IgG (H+L) Antibody Guide

  2026-08-31

  The FITC Goat Anti-Mouse IgG (H+L) Antibody provides fluorescent mouse IgG detection when a mouse primary antibody must be visualized by microscopy or flow cytometry. It is intended for validated fluorescent immunoassays and should not be assumed suitable for non-mouse primary antibodies, nonfluorescent detection systems, or live-cell workflows without addressing its preservative-containing formulation.

• Dimethyloxalylglycine (DMOG): Practical Guide

  2026-08-30

  Dimethyloxalylglycine (DMOG), SKU A4506, is a cell-permeable PHD inhibitor used to stabilize HIF-1α and model hypoxia-related signaling under normoxic conditions. It supports controlled in vitro and preclinical studies of oxygen sensing, inflammation, and infection research, but is not intended for diagnostic, therapeutic, or medical use.

8468 records 1/565 page Next 12345 下5页 Last page